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ditorialross-cultural  comparisons  of  medicinal  ﬂoras—What  are  the  implications  for
ioprospecting?Saslis-Lagoudakis et al. (2011) in their recent publication sug-
est that plant families that are used cross-culturally as a source
or medicinal agents may  have exceptional potential for drug dis-
overy. I disagree with their view primarily because their study
otentially misunderstands the nature of bioprospecting (Tan et al.,
006; McChesney et al., 2007; Harvey, 2008; Li and Vederas, 2009).
t needs to be emphasized that despite medicinal plants being a
ocal source for new drugs in the past, the scientiﬁc literature
hows that recent initiatives to bioprospect ethnomedical ﬂoras
ave unfortunately largely failed, as also correctly cited by the
uthors. While this may  be due to inadequate screening approaches
McChesney et al., 2007; Koehn, 2008; Gertsch, 2009) and the
nherent pharmacological complexity of phytomedicines (Gertsch,
011), at least part of this failure may  also be due to an over-
stimation of the predictive value of ethnopharmacopoeias for
ioprospecting. If typically 10–30% of the local ﬂora is used as
edicine (as shown by others and in this study) it may  be dif-
cult to ﬁnd unique underlying pharmacological principles (new
hemical entities) and new emerging targets, which is principally
hat is being searched for in drug discovery. Reading the article by
aslis-Lagoudakis several fundamental questions emerge that may
lso be relevant for the contemporary discussion on ethnobotanical
nd ethnopharmacological research.
The authors compare three ethnopharmacopoeias (Nepal, New
ealand and the Cape of South Africa) by statistical analysis and
escribe the common ethnomedical usage of 13 plant families.
f I understand them correctly, they conclude that similar usage
ay  be due to the spectrum of common bioactive principles con-
erved within these families. The reason they do not compare
enera or species (which would be much more interesting) is
ecause the respective ﬂoras are too diverse. The concept of cross-
ultural ethnopharmacology as a basis for ﬂagging plants and
ungi for bioprospecting is rather intuitive and not new (Schultes,
969; Wasson, 1979; King and Tempesta, 1994). However, in their
tudy it remains unclear how the authors deﬁne a bioprospect-
ng strategy or what they think bioprospecting is. For molecular
cientists bioprospecting is the process of discovery of bioactive
rinciples or biogenetic materials from natural sources, implying a
olecular approach. Since the Convention on Biological Diversity
ioprospecting also involves a legal framework of issues related
o ownership of biogenetic resources (Tan et al., 2006). Thus,
ioprospecting is about real discoveries, innovations and develop-
ents, mostly of a molecular nature, ultimately leading to patents
nd economic output. Bioprospecting is not about cultural trans-
ission of ethnomedical traditions.
378-8741     © 2011 Elsevier Ireland Ltd.  
oi:10.1016/j.jep.2011.09.017
Open access under CC BY-NC-ND license.What are the fundamental problems in the study by Saslis-
Lagoudakis et al.? First, the argument of bioprospecting in the
context of this study is not a solid one and rather artiﬁcially
imposed. Second, it is debatable whether the common patterns
in ethnomedical usage of plant families between remote ethnic
groups are the result of common medical needs by distant cultures
or whether they indeed reﬂect a convergent usage of plants based
on common pharmacological principles. Third, plant and fungi fam-
ilies, respectively, are biogenetically too diverse to infer a common
phytochemical and ultimately pharmacological basis, with some
notable exceptions (e.g. Grifﬁn and Lin, 2000; Merfort, 2011). One
should not forget that solid research in chemotaxonomy has long
shown the patterns of potentially interesting molecular scaffolds
(Bringmann et al., 2009; Newman and Cragg, 2009; Wallwey and
Li, 2011) and they do not necessarily correlate with plant families.
Maybe part of the problem lies in the transdisciplinary nature of
ethnopharmacology and it is possible that the authors understand
something else by bioprospecting than I do. While for molecular sci-
entists ethnomedical ﬂoras may  be simply phytochemical entities
and conceptually uncoupled from ethnomedical knowledge sys-
tems, the cultural anthropologists just see “chickenwire” when they
talk about molecules. There we have a real problem. I cannot really
see how the study by Saslis-Lagoudakis et al. can help us to improve
the obvious lack of understanding between these disciplines and
how such an ethnobotanical study, being valid and interesting on
its own right, practically improves any bioprospecting strategy. Do
the associations between plant families and ethnomedical cate-
gories really mean anything? The dataset presented in their paper
appears to be a weak basis for regression residual analysis. Rela-
tively few use reports are listed. Moreover, the large plant families
are likely to be overestimated in this type of statistical analysis
(Weckerle et al., 2011) and there is no reason why drug discovery
shall only be made from the big families (several major discover-
ies were made in the small families). In fact, the probability that
major disease categories occur in the big families by chance (!)
is totally neglected in their approach because the focus is on the
statistical representation of plant families within use categories. If
the medicinal plants with multiple medicinal uses (within different
categories) are those that also occur in the different ethnomedical
ﬂoras, the argument that they are “hot” families is perhaps untrue.
Furthermore, they never state explicitly for what exactly the fami-
lies are “hot”. For example, in their analysis the Asteraceae are “hot”
for all sorts of things, ranging from gastrointestinal to neurological
diseases. The strict implication for bioprospecting would thus be
to screen thousands of species of Asteraceae in hundreds of very
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istinct biological assays or focus on the medicinal species within
hose families. Since researchers working in bioprospecting already
now that plant families are potentially interesting for all sorts
f things (e.g. the Asteraceae contain bioactive sesquiterpene lac-
ones) this is not really a breakthrough. What exactly do they mean
y “exceptional potential for discovery of previously overlooked or
ew medicinal plants”? I argue that each individual medicinal plant
pecies has equal exceptional potential unless shown to be untrue
y experimental bioprospecting. As far as I know, there are no solid
ata showing something else. It is a pity that the hypothesis put
orward in this study was not tested in reality, i.e. by applying their
pproach to a real bioprospecting question. One could argue that
 simple statement like “medicines are bitter” may  have greater
redictive value for bioprospecting than this cross-cultural com-
arison as the majority of the drugs so far discovered in plants
re bitter (morphine, digitoxin, quinine, salicylic acid, artemisinine,
amptothecin, paclitaxel, etc.).
There is another general problem with ethnopharmacological
ata in ethnomedical ﬂoras that becomes apparent in this study.
he authors suggest that their statistical analyses of similar or iden-
ical plant usage by distant peoples uncover independent empirical
iscoveries by unrelated ethnic groups, but at the same time point
ut that the placebo effect (meaning response in Moerman and
onas, 2002) may  play a major role in the origin and transmission
f the anecdotal evidence (the only primary data provided). Here
 see a real problem. The uncertainty introduced by the meaning
esponse makes their rational argument very weak. Since I cannot
ioprospect the meaning response, how do I know which plants
eally exert molecular pharmacological effects? What if a certain
lant family is more likely to exert a meaning response within a
ertain disease category, e.g. because they are showy and fragrant?
hat would be a really useful tool for bioprospecting medicinal
lants is a means to differentiate between a meaning response and
olecular pharmacology. I doubt that the cross-cultural compar-
son at the family level provides such a tool. Bioprospecting has
lways been a good argument for the preservation and conservation
f biological resources (Macilwain, 1998). Also, ethnopharmacol-
gy uncovers how humankind has evolved systems of perception
f healing plants (Etkin, 2001; Heinrich et al., 2009). But to bio-
rospect plant families or medicinal plants within these families
hat have been shown to occur in different ethnopharmacopoieas
or the same use category does most likely not solve the problem
s both the categories and the proxies are taken out of the context
Nigh, 2002) and the meaning response contaminates the dataset.
I argue that ethnomedical traditions (often contaminated by
rrational belief systems) are less well suited as a basis for bio-
rospecting than the emerging insights from ecological chemistry.
he application of cheminformatics (chemotaxonomy; structural
harmacophores, etc.) (Zhu et al., 2011; Rollinger et al., 2009;
ringmann et al., 2009; Newman and Cragg, 2009; Wallwey and Li,
011) or the emerging mechanistic ecological insights (Ramesha
t al., 2011) seem to be more promising for bioprospecting and
loser to pharmacological mechanisms than the obscure anecdo-
al evidence commonly found in ethnomedical systems. Anyone
oing ethnobotanical ﬁeld work will sooner or later realize that eth-
omedical knowledge systems are belief systems. We  should not
orget that just because many people believe the same thing over
any generations at different locations (as in religion) it is neces-
arily true. Of course, medicinal plants remain a feasible source for
otential drug leads, but the inherent noise induced by the mean-
ng response seems to make it impossible to ﬁnd the needles in
he haystack. To do bioprospecting we have to be very clear about
hat we are doing and the molecular insights will be decisive about
he outcome. Almost symptomatic, ethnobotanists keep telling us
bout the value of their studies for drug discovery without ever
roving it (see also Leonti, 2011). The authors write: “Methods forcology 139 (2012) 685– 687
identifying common cross-cultural patterns are blunt tools, in com-
parison to the ethnobotanical approaches which might be taken to
deepen our understanding of cultural and contextual impacts of
efﬁcacy, but we argue that they are more likely to permit iden-
tiﬁcation of bioactive plants”. While I agree with the ﬁrst part of
the sentence, I disagree with the second part because, as far as I
know, there are no practical (experimental) examples where this is
corroborated. Of course, there are intriguing molecular correlations
between major taxa and bioactivities, but they are being uncovered
by molecular scientists (Zhu et al., 2011). While advocates of medic-
inal plants keep talking about the potential of medicinal plants the
actual hard-core bioprospecting is being carried out with microbial
and marine natural products (Harvey, 2008; Genilloud et al., 2011)
where believes, hopes or politics do not interfere with the science
so strongly. Without doubt, ethnomedical ﬂoras are highly evolved
dynamic cultural patrimonies and important in numerous health
systems, reﬂecting both biological and cultural diversity, but they
may  not necessarily be a good enough basis to discover new drugs,
despite of their initial success (Gertsch, 2009). Moreover, studies on
ethnomedical ﬂoras may  be useful to establish universal concepts
about phytotherapy and can even lead to rational applications of
botanical drugs. However, being interested in bioprospecting stricto
sensu, I ask what exactly are now the implications for bioprospect-
ing strategies suggested by this study?
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